Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Scancell
The leaked abstract suggests remdesivir provides no benefits for patients - but analysts say conclusions are hard to draw from underpowered trial.
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
This week's roundup includes CEO appointments by Gadeta, Scancell and Zafgen, with various other high-level appointments by Malin Corporation, Cell Medica and Apeiron Biologics.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Scancell Limited
- Scancell Holdings PLC